Exelon® 9.5 mg/24 h

DRUG3 trials

Sponsors

SocraTec R&D GmbH, Zodiac Produtos Farmaceuticos S.A.

Conditions

BioequivalenceBioequivalence Study in Healthy Subjects

Phase 1

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

CompletedNCT03659435

SocraTec R&D GmbHBioequivalence

Start: 2018-08-22End: 2018-11-28Updated: 2019-09-19

Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h)

CompletedNCT05883124

SocraTec R&D GmbHBioequivalence

Start: 2023-04-17End: 2023-07-21Updated: 2024-02-02

Rivastigmine Transdermal Patches Bioequivalence and Adhesion Assessment

CompletedNCT07464340

Zodiac Produtos Farmaceuticos S.A.Bioequivalence Study in Healthy Subjects

Start: 2023-05-12End: 2023-07-03Updated: 2026-03-11

Related Papers

Comparative Bioavailability Study of a Novel Multi-Day Patch Formulationof Rivastigmine (Twice Weekly) with Exelon® Transdermal Patch(Daily)- A Randomized Clinical Trial

Current Alzheimer Research2022-06-019 citations